Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Paclitaxel CAS 33069-62-4 taxal PACLITAXOL PACLITAXEL TAXOL

Paclitaxel CAS 33069-62-4 taxal PACLITAXOL PACLITAXEL TAXOL 

Payment Terms: T/T,D/P,WU 
Place of Origin: Sichuan, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Appearance: White powder
Melting point: 213 °C
Molecular weight: 853.91
Alias: taxal
Production Capacity: 200KG/YEAR
Delivery Date: within 7 days
CAS: 33069-62-4
Solubility: methanol: 50 mg/mL
Storage Condition: 2-8°C
Name: Paclitaxel

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy.

 Paclitaxel ( CAS: 33069-62-4)

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named ittaxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel.

When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane.

Paclitaxel is used to treat patients with lung, ovarian, breast, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis.

Paclitaxel stabilizes microtubules and, as a result, interferes with the normal breakdown of microtubules during cell division. Together withdocetaxel, it forms the drug category of the taxanes. It was the subject of a notable total synthesis by Robert A. Holton of Florida State University.

While offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. There was originally concern because of the environmental impact of its original sourcing (no longer used) from the Pacific yew. In addition, the assignment of rights to Bristol-Myers Squibb and even the name itself were the subject of public debate and Congressional hearings. Clinicians sometimes use the abbreviation "PTX" for paclitaxel, although (like many medical abbreviations) it is not a unique identifier. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.



Molecular   Formula


Molecular weight





White powder

Melting point

213 °C (dec.)(lit.)

Refractive index

-49 ° (C=1, MeOH)


methanol: 50 mg/mL

 Storage Condition


Medical use

Paclitaxel is approved in the UK for ovarian, breast and lung, bladder, prostate, melanoma, esophageal, and other types of solid tumor cancers as well as Kaposi's sarcoma. It is recommended in NICE guidance of June 2001 that it should be used for nonsmall cell lung cancer in patients unsuitable for curative treatment, and in first-line and second-line treatment of ovarian cancer. In September 2001, NICE recommended paclitaxel should be available for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer.

Similar compounds

Albumin-bound paclitaxel (trade name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is bound to albumin nano-particles. Much of the clinical toxicity of paclitaxel is associated with the solvent Cremophor EL in which it is dissolved for delivery.[citation needed] Abraxis BioScience developed Abraxane, in which paclitaxel is bonded to albumin as an alternative delivery agent to the often toxic solvent delivery method. This was approved by the U.S. Food and Drug Administration in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.

Nanoparticle-bound docetaxel is currently being studied in human clinical trials.

Synthetic approaches to paclitaxel production led to the development of docetaxel. Docetaxel has a similar set of clinical uses to paclitaxel and is marketed under the name of Taxotere.

Recently the presence of taxanes including paclitaxel, 10-deacetylbaccatin III, baccatin III, paclitaxel C, and 7-epipaclitaxel in the shells and leaves of hazel plants has been reported. The finding of these compounds in shells, which are considered discarded material and are mass-produced by many food industries, is of interest for the future availability of paclitaxel.


Paclitaxel is used as an antiproliferative agent for the prevention of restenosis (recurrent narrowing) of coronary stents; locally delivered to the wall of the coronary artery, a paclitaxel coating limits the growth of neointima (scar tissue) within stents. Paclitaxel drug eluting coated stents for coronary artery placement are sold under the trade name Taxus byBoston Scientific in the United States. Paclitaxel drug eluting coated stents for femoropopliteal artery placement are sold under the trade name Zilver PTX by Cook Medical, Inc.

Research use

Aside from its direct clinical use, paclitaxel is used extensively in biological and biomedical research as a microtubule stabilizer. In general, in vitro assays involving microtubules, such as motility assays, rely on paclitaxel to maintain microtubule integrity in the absence of the various nucleating factors and other stabilizing elements found in the cell. For example, it is used for in vitro tests of  medicine that aim to alter the behavior of microtubule motor proteins, or for studies of mutant motor proteins. Paclitaxel is sometimes used for in vivo studies as well; it can be fed to test organisms, such as fruit flies, or injected into individual cells, to inhibit microtubule disassembly or to increase the number of microtubules in the cell. Paclitaxel induces remyelination in a demyelinating mouse in vivo and inhibits hPAD2 in vitro though its methyl ester side chain did not. Angiotech Pharmaceuticals Inc. began phase II clinical trials in 1999 as a multiple sclerosis treatment but in 2002, reported that the results showed no statistical significance.

Related Information 

Apperance:white crystal powder

Risk phrases:R40; R41;

Safety term :S26; S36/37/39; S45;

Application:Broad-spectrum antitumor plant medicine

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: